Nephrol Dial Transplant (2003) 18: 2088-2096
© 2003 European Renal Association-European Dialysis and Transplant Association
Original Article
Increased platelet–monocyte aggregates and cardiovascular disease in end-stage renal failure patients
1Department of Renal Medicine and Transplantation and 2Department of Haematology, St Bartholomew’s and the Royal London Hospitals, London, UK
Correspondence and offprint requests to: Dr Marion G. Macey, Department of Haematology, The Royal London Hospital, Whitechapel, London E1 1BB, UK. Email: marion.macey{at}bartsandthelondon.nhs.uk
Background. Atherosclerotic cardiovascular disease is a major cause of morbidity and mortality in patients with end-stage renal disease. This excess morbidity cannot be entirely explained by well-recognized conventional and novel risk factors alone, and occurs irrespective of dialysis modality. Recent evidence suggests that the activation of platelets and their interaction with circulating cells are important independent risk factors for atherosclerosis in non-uraemic patients. We therefore studied platelet activation and circulating platelet–leucocyte aggregates in stable patients without evidence of cardiovascular disease on continuous ambulatory peritoneal dialysis (CAPD) and haemodialysis and investigated an association with cardiovascular events.
Methods. Immunofluorescent flow cytometry was used to measure the percentage of P-selectin- (CD62P) positive platelets, the percentage of platelet–neutrophil and platelet–monocyte aggregates, and the expression of the P-selectin ligand, P-selectin glycoprotein ligand-1 (PSGL-1, CD162) on leucocytes in haemodialysis and CAPD patients and normal controls. The platelet count and the mean platelet component (MPC, a measure of platelet activation) were determined on the ADVIATM 120 Haematology System (Bayer, NY).
Results. Platelet activation as assessed by MPC or CD62P expression was significantly increased in haemodialysis but not CAPD patients compared with controls. Circulating platelet–monocyte aggregates were significantly increased in parallel with a significant reduction in PSGL-1 expression on monocytes in both patient groups compared with normal controls. The presence of higher platelet–monocyte aggregates in dialysis patients was associated with increased cardiovascular events.
Conclusion. We describe increased platelet–monocyte aggregates with reduced leucocyte PSGL-1 expression in patients with end-stage renal disease irrespective of dialysis modality, associated with an increased risk of cardiovascular disease. These findings may suggest a novel mechanism by which accelerated atherosclerosis occurs in uraemic patients.
Keywords: CD62P; dialysis; platelet–monocyte aggregates; platelets; PSGL-1
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Bournazos, J. Rennie, S. P. Hart, K. A.A. Fox, and I. Dransfield Monocyte Functional Responsiveness After PSGL-1-Mediated Platelet Adhesion Is Dependent on Platelet Activation Status Arterioscler. Thromb. Vasc. Biol., August 1, 2008; 28(8): 1491 - 1498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bournazos, J. Rennie, S. P. Hart, and I. Dransfield Choice of Anticoagulant Critically Affects Measurement of Circulating Platelet-Leukocyte Complexes Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): e2 - e3. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Goubareva, E. Gkaliagkousi, A. Shah, L. Queen, J. Ritter, and A. Ferro Age decreases nitric oxide synthesis and responsiveness in human platelets and increases formation of monocyte-platelet aggregates Cardiovasc Res, September 1, 2007; 75(4): 793 - 802. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Guessous, M. Marcinkiewicz, R. Polanowska-Grabowska, S. Kongkhum, D. Heatherly, T. Obrig, and A. R. L. Gear Shiga Toxin 2 and Lipopolysaccharide Induce Human Microvascular Endothelial Cells To Release Chemokines and Factors That Stimulate Platelet Function Infect. Immun., December 1, 2005; 73(12): 8306 - 8316. [Abstract] [Full Text] [PDF]
|
|